Xenon Pharmaceuticals (XENE) Cash from Financing Activities (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Cash from Financing Activities data on file, last reported at $843.0 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 73141.79% year-over-year to $843.0 million in Q1 2026; TTM through Mar 2026 was $959.0 million, a 7120.65% increase from a year earlier, with the FY2025 full-year figure at $117.1 million, up 865.48% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $843.0 million, up from $113.5 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for XENE reached as high as $843.0 million in Q1 2026 and fell as low as $6000.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $143.2 million across 5 years, with a median of $7.9 million in 2022.
• Across the five-year window, Cash from Financing Activities slumped 100.0% in 2022 and surged 5400133.33% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $6000.0 in 2022, then jumped by 5400133.33% to $324.0 million in 2023, then tumbled by 96.26% to $12.1 million in 2024, then surged by 836.0% to $113.5 million in 2025, then jumped by 642.5% to $843.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $843.0 million in Q1 2026, $113.5 million in Q4 2025, and $2.4 million in Q3 2025.